Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Olumiant - withdrawal of application for variation to marketing authorisation

Olumiant - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

baricitinib
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Olumiant
  • More information on Olumiant

Overview

Eli Lilly Nederland B.V. withdrew its application for the use of Olumiant in the treatment of patients hospitalised with COVID-19.

The company withdrew the application on 7 December 2022.

Olumiant is a medicine used in adults for treating:

  • moderate to severe rheumatoid arthritis (a disease causing inflammation of the joints) when standard treatment with disease?modifying anti?rheumatic drugs (also known as ‘DMARDs’) has not worked well enough or if patients cannot tolerate them. Olumiant can be used either alone or in combination with the disease-modifying drug methotrexate;
  • moderate to severe atopic dermatitis (eczema) when treatments applied to the skin are not sufficient or appropriate;
  • severe alopecia areata (a disease causing hair loss of the scalp and/or other parts of the body).

Olumiant has been authorised in the EU since February 2017. It contains the active substance baricitinib and is available as tablets to be taken by mouth.

The company applied to extend the use of Olumiant to include the treatment of adults and children aged 10 years and older hospitalised with COVID 19 requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation). During the assessment of the application, the company modified the application to the treatment of adults with COVID-19 who require low-flow oxygen or non-invasive ventilation/high-flow oxygen.

The active substance in Olumiant, baricitinib, is an immunosuppressant (a medicine that reduces the activity of the immune system). It works by blocking the action of enzymes known as Janus kinases. These enzymes play an important role in the processes of inflammation and damage that occur in rheumatoid arthritis, atopic dermatitis and alopecia areata. By blocking these enzymes, baricitinib reduces joint, skin and hair follicle inflammation and other symptoms of these diseases.

In patients hospitalised with COVID-19, Olumiant was expected to work in the same way as it does in its existing indication(s), but also by directly keeping the SARS-CoV-2 virus from entering the body’s cells.

The company presented the results from three studies in patients hospitalised with COVID-19.

In one study, around 1,000 patients were given Olumiant or placebo (a dummy treatment), in combination with remdesivir (an antiviral medicine used to treat COVID-19). The main measure of effectiveness was the time it took patients to recover. In another study, about 1,500 patients received Olumiant or placebo. This study investigated if the medicine prevented worsening of disease or death. A third study in over 8,000 patients compared treatment with Olumiant and placebo and looked at prevention of death.

The application was withdrawn after the European Medicines Agency had evaluated the information from the company and had prepared questions for the company. After the Agency had assessed the company’s responses to the questions, there were still some unresolved issues.

Based on the review of the information and the company’s responses to the Agency’s questions, at the time of the withdrawal, the Agency had some concerns and its provisional opinion was that Olumiant could not have been authorised for the treatment of COVID-19. The Agency considered that the evidence submitted by the company did not conclusively demonstrate that the medicine provides meaningful benefits to patients. Therefore, at the time of the withdrawal, the Agency’s opinion was that the benefit/risk balance of Olumiant was negative.

In its Withdrawal letter : Olumiant (II-0028) notifying the Agency of the withdrawal of application, the company stated that its withdrawal is based on the Agency’s opinion that available data were not sufficient to conclude on a positive benefit-risk balance for the proposed indication.

The company informed the Agency that there are no consequences for patients in clinical trials using Olumiant.

If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.

There are no consequences on the use of Olumiant in its authorised uses.

Questions and answers on the withdrawal of application to change the marketing authorisation for Olumiant (baricitinib)

Reference Number: EMA/931846/2022

English (EN) (130.83 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View
Other languages (22)

български (BG) (129.84 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

español (ES) (106.95 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

čeština (CS) (124.94 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

dansk (DA) (106.76 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

Deutsch (DE) (107.41 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

eesti keel (ET) (105.96 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

ελληνικά (EL) (131.02 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

français (FR) (107.33 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

hrvatski (HR) (120.89 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

italiano (IT) (106.69 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

latviešu valoda (LV) (127.35 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

lietuvių kalba (LT) (125.02 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

magyar (HU) (121.58 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

Malti (MT) (126.1 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

Nederlands (NL) (107.36 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

polski (PL) (124.99 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

português (PT) (106.93 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

română (RO) (123.4 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

slovenčina (SK) (123.49 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

slovenščina (SL) (120.01 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

Suomi (FI) (106.3 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

svenska (SV) (106.13 KB - PDF)

First published: 16/12/2022Last updated: 02/02/2023
View

Key facts

Name of medicine
Olumiant
EMA product number
EMEA/H/C/004085
Active substance
Baricitinib
International non-proprietary name (INN) or common name
baricitinib
Therapeutic area (MeSH)
Arthritis, Rheumatoid
Anatomical therapeutical chemical (ATC) code
L04AA37
Marketing authorisation holder
Eli Lilly Nederland B.V.
Date of issue of marketing authorisation valid throughout the European Union
13/02/2017
Date of withdrawal
07/12/2022

Documents

Withdrawal assessment report for Olumiant (II-0028)

AdoptedReference Number: EMA/926734/2022

English (EN) (5.8 MB - PDF)

First published: 02/02/2023
View

Withdrawal letter : Olumiant (II-0028)

English (EN) (9.41 KB - PDF)

First published: 16/12/2022
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Olumiant

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023
15/09/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023
21/07/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022
16/12/2022
EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
28/10/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022
20/05/2022
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022
11/02/2022
EMA starts evaluating use of Olumiant in hospitalised COVID-19 patients requiring supplemental oxygen
29/04/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020
18/09/2020
New oral treatment for moderate to severe atopic dermatitis
18/09/2020
New oral treatment for rheumatoid arthritis
16/12/2016
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016
16/12/2016

More information on Olumiant

  • Olumiant
This page was last updated on 02/02/2023

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union